



May 31, 2023

NEWS RELEASE

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)

TMS Co., Ltd. to participate in the Jefferies Healthcare Conference

TMS Co., Ltd. (the “Company”) announces that Takuro Wakabayashi, MBA, Chief Executive Officer of the Company will be presenting a corporate overview at the Jefferies Healthcare Conference being held in person in New York City, USA on June 7 - 9, 2023.

The Company will host one-on-one meetings on Thursday, 8 June at the Conference.

Please contact Jefferies representatives to schedule a one-on-one meeting with the Company during the conference.

About TMS

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address medical unmet needs. The Company’s pipeline consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus. The lead pipeline, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipelines by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit www.tms-japan.co.jp/en.

Investor and Media Contact:
ir@tms-japan.co.jp

End